Things are looking up for our European readers. It must be frustrating for people outside of the United States to read this blog and learn about the many advances we now have in the US which are not available to them. The good news is that Sanofi has just launched Jevtana (cabazitaxel) in the UK [...]
Yesterday Dendreon, the producers of Provenge, received word from the FDA that their plant in California had been approved to manufacture Provenge. This afternoon they received a positive response from the Centers for Medicare and Medicaid Services (CMS) that a final National Coverage Decision (NCD) for Provenge has been issued requiring Medicare contractors to cover [...]
Darryl, the Malecare Executive Director, posted an organizational response to yesterday's New York Times Article on the newly approved advanced prostate cancer drugs and their economic impact. I thought that I would share his insightful post with everyone. "We can easily price commodities and drugs to whatever the market will bare, but how do we [...]
Today’s New York Times carried a front page article about the high cost of the new prostate cancer treatments. This article seems to be the talk of the town and the talk (based on the comments that have been entered on-line) has been anything but positive. Unfortunately, many of the comments have made with the [...]
Dear Friends, If you love the work of Malecare Cancer Support, then tell the world! You may or may not realize it, but Malecare has grown to become America's largest men's cancer survivor support and advocacy national nonprofit. Malecare is a 13-year-old all volunteer organization, and our mission is to help men and their families [...]
The Naval Fleet Reserve Association recently provided the following information regarding updates of the Veterans Administration list of vessels exposed to Agent Orange during the Vietnam conflict. This will include many more veterans eligible for VA care for the many diseases attributed to this product. […]
There is a constant debate between both oncologist and advocates about the value and safety of 5-alpha-reductase inhibitors (Proscar and Avodart) both in the early treatment and later treatment of men with prostate cancer. In fact, I have had an on-going private debate with one very knowledgeable educator advocate over this issue. I often have [...]
YOUR DEADLINE: WEDNESDAY, JUNE 22, 2011 On Wednesday and Thursday, the House will meet at 10:00 a.m. for Morning Hour debate and 12:00 p.m. for legislative business. H.R. 2219, the Department of Defense Appropriations Act, 2012 (Rep. Young (FL) - Appropriations), has been placed on the House calendar for then. As part of H.R. 2219 [...]
From Anthony Hardie, Madison, Wis. All: I've just gone through the full Defense Committee bill (before yesterday's markup) and the corresponding report language on the various CDMRP programs. The results are below. FY12 Defense Appropriations -- Full Committee Bill (before yesterday's markup): 1. Several programs would not be funded at all: most notably the sort [...]
U.S. SENATE: Save the Prostate Cancer Research Program Now it is time to write your U.S. Senators - TODAY! A few weeks ago I requested that you write to your member of the House of Representatives, now it is time to write to the other side of congress, the Senate. Write your U.S. Senators today [...]
